Aripiprazole Tablet
Product Images NDC 63629-7108

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 63629-7108). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 1 (Image Fig1 Effectofotherdrug Arip)

This is a table presenting the effects of various drugs on the pharmacokinetics of aripiprazole. The table lists drugs that either inhibit or induce certain enzymes, gastric acid blockers, or other drugs such as valproate, lithium, and lorazepam. Fold change and 90% confidence intervals of aripiprazole are shown relative to the reference (without interacting drug).*

FDA Label Image

Image 2 (Image Fig2 Effectofotherdrug Dehydroarip)

FDA Label Image

Image 3 (Image Fig3 Effectofarip Otherdrug)

This is a table depicting the effects of aripiprazole on the pharmacokinetics of various drugs. The table contains data on the changes seen in drug metabolism, expressed as fold change and 50% confidence interval. The drugs studied include deropmetoptan, cvpace, artann, Roartain S, omeprazole, UoTiAd, lamotigine, valproate, lithium, lorazepam, venidaine, Odesmyhenataing, and escitiopram. The relative change in pharmacokinetics is shown on the X-axis, ranging from 0 to 30.*

FDA Label Image

Image 4 (Image Fig4 Effectofintrinsicfactor Arip)

This appears to be a table or a figure related to pharmacokinetics of aripiprazole for different populations based on intrinsic factors such as age, gender, and hepatic or renal impairment. It shows the fold change and 90% confidence interval for different parameters such as AUC and Cmax in different populations as compared to a reference group. Without the actual values or units, it is not possible to provide specific information about the pharmacokinetics of aripiprazole.*

FDA Label Image

Image 5 (Image Fig5 Effectofintrinsicfactor Dehydroarip)

The text describes a figure showing the effects of intrinsic factors on the pharmacokinetics of dehydro-aripiprazole. The factors considered include CYP2D6 metabolizer status, age, gender, hepatic impairment, and renal impairment. The figure presents fold change and S0% CI for each factor on AUC and Cmax, with separate comparisons for different levels of each factor (e.g., poor vs. extensive CYP2D6 metabolizers). The figure also includes a line graph of the relative change in pharmacokinetics compared to a reference group.*

FDA Label Image

Fig 6 (Image Fig6 Schizophreniastudy 5)

This is a graph depicting the proportion of patients with relapse in a schizophrenia study (Study 5) using Kaplan-Meier estimation. The graph compares the proportion of relapse between patients who received Aripiprazole and those who were given a placebo. The number of subjects at risk is shown below the graph for each treatment group. The x-axis is the number of days from randomization, and the y-axis represents the cumulative proportion of patients with relapse.*

FDA Label Image

7 (Image Fig7 Bipolarstudy 7)

FDA Label Image

8 (Image Fig8 Bipolarstudy 8)

The figure shows the Kaplan-Meier estimation of the cumulative proportion of patients who experienced a relapse to any mood event in Bipolar Study 8. The proportion of patients with relapse is plotted on the y-axis and the days from randomization are plotted on the x-axis. The two treatment groups compared are ABILIFY and LACE 169. There are some illegible characters in the text.*

FDA Label Image

9 (Image Fig9 Tourettesdisorderstudy1)

This is a graphical representation of the least square means of change from baseline in YGTSS TTS for Tourette's Disorder Study 1. The graph depicts the change in YGTSS total tic score from baseline, and displays the data for 5 time points (weeks) of treatment. The values are presented in a tabular format, with the least square means of change in YGTSS score being presented for each week of treatment. The data may be useful for evaluating treatment efficacy in patients with Tourette's Disorder.*

FDA Label Image

Image (Image Logo Medguide)

FDA Label Image

Logo (Image Logo Pi)

FDA Label Image

Description Image (Image Structure)

Not available.*

FDA Label Image

Label (Lbl636297108)

This is information about a medication called Abilify 15mg Tablet, with its manufacturer and packaging details. It also includes a warning to keep all drugs out of the reach of children.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.